Global DPP-IV Inhibitors Industry

Wednesday, October 17, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Oct. 16, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million.Read

the full report: https://www.reportlinker.com/p05591547 The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Others. The US market is further analysed in terms of sales by the following drug Segments:
Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 14 companies including many key and niche players such as:- AstraZeneca Plc- Boehringer Ingelheim GmbH- Eli Lilly and Company- Merck & Co, Inc.- Mitsubishi Tanabe Pharma Corporation- Novartis AGRead the full report: https://www.reportlinker.com/p05591547 DPP-IV INHIBITORS MCP-6MARKET ANALYSIS, TRENDS, AND FORECASTS, SEPTEMBER 2CONTENTS 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study 2. INDUSTRY OVERVIEW Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date Table 1: Global DPP-4 Inhibitor Market by Top Five Drug Class (2018): Market Share Breakdown of Revenues (In %) for Januvia/Janumet, Galvus, Onglyza, Tradjenta, and Nesina (includes corresponding Graph/Chart) TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label Management of T2DM with DPP-4 Combination Therapy FDA Approves Merck’s First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy Table 2: Prices of Select Dpp4 and Sglt-2 Inhibitors: Single and Combination Drugs 3. THE DIABETES EPIDEMIC Key Diabetes Statistics Table 3: World Diabetes and Population Statistics (2017 & 2045) (includes corresponding Graph/Chart) Table 4: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes by Region for 2017 and 2045 (includes corresponding Graph/Chart) Table 5: Global Prevalence (%) of Diabetes in Adults (20-79) by Region for the Years 2017 and 2045 (includes corresponding Graph/Chart) Table 6: Global Prevalence of Diabetes - Number of Adults Diagnosed with Diabetes (in Million) by Gender for the Year 2017 (includes corresponding Graph/Chart) Table 7: Worldwide Diabetes Prevalence (%) in Adults by Age Group and Gender for the Year 2017 (includes corresponding Graph/Chart) Table 8: Diabetes Prevalence in Rural and Urban Areas - Number of Adults with Diagnosed Diabetes (in Million) in Urban and Rural Areas for 2017 and 2045 (includes corresponding Graph/Chart) Table 9: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2017 and 2(includes corresponding Graph/Chart) Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market Table 10: Healthcare Spending (in US$ Billion) by People with Diabetes (20-79 Years) for the Years 2011, 2013, 2015 and 2017 (includes corresponding Graph/Chart) Table 11: Health Spending due to Diabetes in Adults (20-years) - Breakdown by Region for the Years 2017 and 2(includes corresponding Graph/Chart) Table 12: Health Expenditure due to Diabetes by Adults in Select Countries for the Year 2017 (includes corresponding Graph/Chart) 4. AN OVERVIEW OF DRUG CLASSES IN ANTI- DIABETIC DRUGS CATEGORY DPP-4 Inhibitors - Complementing Existing Approaches Rationale for Use of DPP-4 Inhibitors Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction DPP-IV Inhibitors Vis-à-vis SGLT2 Inhibitors DPP-4 Inhibitors versus GLP-1 Receptor Agonists Distinction between GLP-1 Receptor Agonists and DPP-4 Inhibitors DPP-4 Inhibitors versus Sulfonylureas 5. A REVIEW OF SELECT APPROVED DPP-IV INHIBITOR DRUGS The DPP-4 Inhibitor Domain Select Approved DPP-4 Inhibitors Available in Developed Markets Januvia - The Leading DPP-IV Inhibitor Drug Worldwide Januvia® Franchise (Merck & Co.) Table 13: Global Sales of Januvia (Sitagliptin) Franchise by Region (2015-2024): Value Sales in US$ Million for US and RoW (includes corresponding Graph/Chart) Table 14: World 10-Year Perspective for Januvia (Sitagliptin) Franchise Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart) Galvus (Novartis) Table 15: Global Sales of Galvus (2015-2024): Value Sales in US$ Million (includes corresponding Graph/Chart) A Comparison of Januvia and Galvus Pharmacological Comparison of Sitagliptin and Vildagliptin Onglyza (AstraZeneca) Table 16: Global Sales of Onglyza (Saxagliptin) by Region (2015-2024): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart) Table 17: Global 10-Year Perspective for Onglyza (Saxagliptin) Sales Breakdown for Years 2015, 2018 and 2for the US and RoW (includes corresponding Graph/Chart) Tradjenta (Boehringer Ingelheim) Table 18: Global Sales of Tradjenta (Linagliptin) by Region (2015-2024): Value Sales in US$ Million for US and RoW (includes corresponding Graph/Chart) Table 19: Global 10-Year Perspective for Tradjenta (Linagliptin) Sales Breakdown for Years 2015, 2018 and 2for the US and RoW (includes corresponding Graph/Chart) Nesina (Takeda Pharmaceutical) Table 20: Global Sales of Nesina (Alogliptin) by Region (2015-2024): Value Sales in US$ Million for US and RoW (includes corresponding Graph/Chart) Table 21: Global 10-Year Perspective for Nesina (Alogliptin): Annual Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart) TENELIA (Mitsubishi Tanabe & Daiichi Sankyo Co., Ltd.) ZAFATEK (Takeda Pharmaceutical) MARIZEV (Merck) 6. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS Physiology of Glucose Homeostasis Glucose Homeostasis in the Fasting Stage Glucose Homeostasis in the Fed Stage What is DPP-4? Introduction to DPP-4 Inhibitors Mechanism of Action of DPP-4 Inhibitors Schematic Representation of DPP-IV Inhibitor’ Mechanism of Action DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications Advantages of DPP-4 Inhibitors Type-2 Diabetes - The Most Prevalent Form of Diabetes Bio-chemistry of T2DM 7. COMPETITIVE LANDSCAPE 7.1 Focus on Select Global Players AstraZeneca Plc. (UK) Boehringer Ingelheim GmbH (Germany) Eli Lilly and Company (USA) Merck & Co, Inc. (USA) Mitsubishi Tanabe Pharma Corporation (Japan) Novartis AG (Switzerland) Takeda Pharmaceutical Company Limited (Japan) 7.2 Recent Industry Activity MSD Receives Marketing Approval for SUJANU® Combination Tablets in Japan Boehringer Ingelheim and Lilly Announces Cardiovascular Outcome Trial for Tradjenta's CARMELINA® Fixed-Dose Combination STEGLUJAN™ Receives Approval from US FDA AstraZeneca Receives FDA Approval for Qtern Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd. Announces the Launch of CANALIA® Combination Tablets Merck Drops Omarigliptin Filing in the US and EU FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines First Real-world Evidence Hints at Greater Efficacy of SGLTInhibitors BoehringerIngelheim Pharmaceuticals, Inc. and Eli Lilly and Company Receives FDA Approval for Glyxambi® Tablets 8. GLOBAL MARKET PERSPECTIVE Table 22: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 23: World 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart) Table 24: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 25: World 10-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart) Table 26: World Recent Past, Current and Future Analysis for Sitagliptin by Geographic Region/Country - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 27: World 10-Year Perspective for Sitagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2(includes corresponding Graph/Chart) Table 28: World Recent Past, Current and Future Analysis for Saxagliptin by Geographic Region/Country - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 29: World 10-Year Perspective for Saxagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2(includes corresponding Graph/Chart) Table 30: World Recent Past, Current and Future Analysis for Linagliptin by Geographic Region/Country - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 31: World 10-Year Perspective for Linagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2(includes corresponding Graph/Chart) Table 32: World Recent Past, Current and Future Analysis for Alogliptin by Geographic Region/Country - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 33: World 10-Year Perspective for Alogliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2(includes corresponding Graph/Chart) 9. REGIONAL MARKET PERSPECTIVE 9.1 The United States A.Market Analysis List of FDA-Approved DPP-4 Inhibitors in the US Januvia Leads the Way, FDA’s Heart Failure Warning Impacts Performance Table 34: The US DPP-4 Inhibitors Market by Leading Brands (2018): Market Share Breakdown of Revenues for Januvia/Janumet, Tradjenta, Onglyza, and Nesina (includes corresponding Graph/Chart) FDA’s Latest Issue of Heart Failure Warning on DPP-Inhibitors - Potential Market Threat Increasing Diabetes Incidence in the US Table 35: Diabetes and Population Statistics in North America and Caribbean Region (2017 & 2045) (includes corresponding Graph/Chart) Table 36: Diabetes Statistics in the US (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes (‘000s), and Number of Diabetes-Related Deaths (in ‘000s) B.Market Analytics Table 37: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Linagliptin and Alogliptin Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 38: The US 10-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Linagliptin and Alogliptin Drugs Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart) 9.2 Canada A.Market Analysis Diabetes Statistics Table 39: Diabetes Statistics in Canada (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes (‘000s), and Number of Diabetes-Related Deaths (in ‘000s) Table 40: Adult Diabetes in Canada (2017E): Percentage Share Breakdown of Diabetic Population by Gender (includes corresponding Graph/Chart) Table 41: Adult Diabetes in Canada (2017E): Percentage Share Breakdown of Diabetic Population by Age Group (includes corresponding Graph/Chart) B.Market Analytics Table 42: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.3 Japan A.Market Analysis Japan - An Important Market for DPP-IV Inhibitors Table 43: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) List of DPP-4 Inhibitors in the Japanese Market B.Market Analytics Table 44: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4 Europe A.Market Analysis Current & Future Analysis DPP-IV Inhibitors Available in the European Market Diabetes Statistics in Europe Table 45: Diabetes and Population Statistics in Europe (2017 & 2045) (includes corresponding Graph/Chart) Table 46: Diabetes Statistics in Europe (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes Prevalence (%), Adults with Undiagnosed Diabetes ('000s) and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) B.Market Analytics Table 47: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 48: European 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Russia, and Rest of Europe Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart) 9.4.1 France Market Analysis Table 49: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4.2 Germany Market Analysis Table 50: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4.3 Italy Market Analysis Table 51: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4.4 The United Kingdom A.Market Analysis Table 52: Diabetes Statistics in the UK (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes ('000s) and Number of Diabetes-Related Deaths (in ‘000s) Rising Obesity Cases - Increased Risk of Diabetes NHS England Launches Action for Diabetes Plan B.Market Analytics Table 53: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4.5 Russia A.Market Analysis Rising Diabetes Prevalence Presents Opportunity for DPP-IV inhibitors Market Table 54: Diabetes Statistics in Russia (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes ('000s) and Number of Diabetes-Related Deaths (in ‘000s) (includes corresponding Graph/Chart) B.Market Analytics Table 55: Russian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.4.6 Rest of Europe Market Analysis Table 56: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.5 Asia-Pacific A.Market Analysis Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors Aging Populace - Potential Opportunities Table 57: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart) Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities Table 58: Diabetes and Population Statistics in Western Pacific (2017 & 2045) (includes corresponding Graph/Chart) Table 59: Diabetes Statistics in Western Pacific (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed diabetes ('000s) and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) Table 60: Diabetes and Population Statistics in South East Asia (2017 & 2045) (includes corresponding Graph/Chart) Table 61: Diabetes Statistics in South East Asia (2017) - Number of Adults with Diabetes (20-79) (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes ('000s) and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) China & India Offer High Potential Asia Suffers from Lack of Focus on Diabetes Care Healthcare Societies and Associations Spread Awareness of Diabetes B.Market Analytics Table 62: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) Table 63: Asia-Pacific 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, South Korea, and Rest of Asia-Pacific Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart) 9.5.1 China A.Market Analysis Current & Future Analysis China: A Market with Huge Untapped Potential for DPP-Inhibitor Drugs Table 64: Diabetes Statistics in China (2017) - Number of Adults with Diabetes (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes (in ‘000s), and Number of Diabetes-Related Deaths (in ‘000s) Robust Growth Ahead Despite Initial Lag B.Market Analytics Table 65: Chinese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.5.2 India A.Market Analysis DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition Diabetic Epidemic in the Country to Spur Market Growth Table 66: Diabetes Statistics in India (2017) - Number of Adults with Diabetes (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes (in ‘000s), and Number of Diabetes-Related Deaths (in ‘000s) B.Market Analytics Table 67: Indian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.5.3 South Korea A.Market Analysis Rising Competition in the Korean DPP-4 Inhibitor Market B.Market Analytics Table 68: South Korean Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 9.5.4 Rest of Asia-Pacific A.Market Analysis Current & Future Analysis Australia Rising Incidence of Diabetes Australia: Rising Diabetes Prevalence Presents Opportunity for DPP-IV inhibitors Market Table 69: Diabetes Population in Australia (2017): Percentage Breakdown of Number of Individuals with Diabetes by Age Group (includes corresponding Graph/Chart) B.Market Analytics Table 70: Rest of Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2(includes corresponding Graph/Chart) 9.6 Rest of World A.Market Analysis Current & Future Analysis Latin America: National Diabetes Programs Diabetes in Latin America - A Glance at Key Statistics Table 71: Diabetes and Population Statistics in South & Central America (2017 & 2045) (includes corresponding Graph/Chart) Table 72: Diabetes Statistics in South & Central America (2017) - Number of Adults with Diabetes (20-79 (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed Diabetes) ('000s), and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) Key Opportunity Indicator: Aging Population Table 73: Aging Population in Latin America and the Caribbean by Region (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart) Table 74: Aging Population in Latin America (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population by Country (includes corresponding Graph/Chart) A Peek at Brazilian Diabetes Market United Arab Emirates: Rising Diabetic Cases to Propel Market Demand Key Statistics: Diabetes Prevalence in Middle East and African Regions Table 75: African Diabetes and Population Statistics (2017& 2045) (includes corresponding Graph/Chart) Table 76: Diabetes Statistics in Africa (2017) - Number of Adults (20-79) with Diabetes (in ‘000s), Diabetes National Prevalence (%), Adults with Undiagnosed diabetes (20-79) ('000s), and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) Table 77: Diabetes and Population Statistics in Middle East and North Africa for 2017 and 2045 (includes corresponding Graph/Chart) Table 78: Diabetes Statistics in Middle East and North Africa (2017) - Number of Adults with Diabetes (in 000s), Diabetes National Prevalence (%), Adults with Undiagnosed diabetes (20-79) ('000s), and Number of Diabetes-Related Deaths (in ‘000s) for Select Countries (includes corresponding Graph/Chart) B.Market Analytics Table 79: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart) 10. COMPANY PROFILES Total Companies Profiled: The United States (2) Japan (6) Europe (3) - Germany (1) - The United Kingdom (1) - Rest of Europe (1) Asia-Pacific (Excluding Japan) (3) Read the full report: https://www.reportlinker.com/p05591547 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/global-dpp-iv-inhibitors-industry-300732297.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store